CD6 and pancreatic neoplasm: CD6 ligands have been extensively studied in cancer biology because of their correlation with higher occurrence of metastases, higher relapse rate, and poor prognosis in breast, lung, prostate, colon, melanoma, renal, hepatocellular, acute myeloid leukemia, and pancreatic cancers.